# Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

> **NCT00424346** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 274 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00424346
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-09
- **Final completion:** 2009-10
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424346, "Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00424346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*